Inhibrx Announces Participation in Upcoming Investor Conference

Rhea-AI Summary

Inhibrx, a clinical-stage biotechnology company (NASDAQ: INBX), announced its participation in the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:40 a.m. Pacific Time. This virtual presentation will showcase its novel biologic therapeutic candidates in oncology and orphan diseases, utilizing its proprietary sdAb platform. Attendees can access the live webcast through Inhibrx's investor website, which will remain available for 60 days post-event. The company collaborates with major biotech firms, enhancing its research capabilities.

SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference:

• 2021 Cantor Virtual Global Healthcare Conference; Wednesday, September 29th, at 8:40 a.m. Pacific Time

The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event.

About Inhibrx, Inc.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conference-301375171.html

SOURCE Inhibrx, Inc.

FAQ

When will Inhibrx present at the Cantor Virtual Global Healthcare Conference?

Inhibrx will present at the Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:40 a.m. Pacific Time.

How can I access the Inhibrx conference presentation?

You can access the Inhibrx conference presentation via a live webcast link on their investor website.

What is the focus of Inhibrx's biotechnology development?

Inhibrx focuses on developing novel biologic therapeutic candidates in oncology and orphan diseases.

What technology does Inhibrx utilize in its drug development?

Inhibrx utilizes its proprietary sdAb platform for protein engineering in drug development.

How long will the Inhibrx webcast be available after the conference?

The Inhibrx webcast will be available for 60 days following the conference.